Skip to main content

Table 3 Selected clinical trial with immunotherapy for advanced HCC

From: Emerging therapies in advanced hepatocellular carcinoma

NCT number Treatment Target Outcome Phase
NCT02702401 Pembrolizumab vs best supportive care PD-1 PFS, OS Phase III
NCT02576509 Nivolumab vs sorafenib PD-1 OS Phase III
NCT02519348 Durvalumab + tremelimumab vs durvalumab monotherapy PD-L1/CTLA-4 Adverse events Phase II
NCT03298451 Durvalumab vs durvalumab + tremelimumab vs sorafenib
NCT01658878 Nivolumab vs nivolumab + ipilimumab vs sorafenib PD-L1/CTLA-4 ORR Phase I/II
  1. PD-1 programmed cell death protein-1, PD-L1 programmed death-ligand 1, CTLA-4 cytotoxic T-lymphocyte-associated protein-4, OS overall survival, PFS progression free survival, ORR overall response rate